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INTRODUCTION 
Seizures are one of the most common neurological problem that occur in 
children. It is defined as a transient occurrence of signs and symptoms that 
occurs due to abnormal excessive neuronal activity1. It is associated with a high 
degree of mortality and morbidity. Several aspects of a child’s life are affected 
including scholastic performance and peer relationships. 
Four to ten percent of children suffer at least one episode of seizure in 
the first 16 years of life. The incidence is highest during the first three years of 
age, then gradually decreases as the child ages2.About 1% of all emergency 
department visits are accounted to seizures. 
The incidence of epilepsy (recurrent unprovoked seizures) in children 
and adolescents seems relatively constant across different populations studied, 
ranging from 50 to 100/l00,000 person-years3. Febrile seizures have been 
reported to be the most common cause of seizures in pediatric population. The 
risk of developing epilepsy after one episode of afebrile seizure is around 30%, 
the incidence decreases to 20% if the neurological examination, EEG and 
imaging are normal. 
Epilepsy is a disorder characterised by a predisposition to generate 
seizures and by the neurobiological, cognitive, psychologic and social 
consequences of the condition. The annual prevalence rate is around 0.5-1%. 
Therefore, a single episode of febrile seizure does not necessarily imply 
epilepsy disorder. 
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Seizure disorder is a generalised terminology that includes epilepsy, 
febrile seizures, symptomatic seizures secondary to CNS infections, metabolic 
conditions, electrolyte disturbances etc. 
An epileptic syndrome is a disorder that manifests as a characteristic 
seizure type that has a particular age of onset and prognosis. Epileptic 
encephalopathy is a syndrome associated with severe EEG abnormalities that 
causes cognitive impairment in the affected individuals. 
The four major epilepsy syndrome classification includes4 
1. Epilepsies of unknown cause of infants and childhood 
2. Familial autosomal dominant epilepsy 
3. Structural metabolic focal epilepsy 
4. Generalised epilepsy of unknown cause 
Majority of the seizure disorder around 60% are idiopathic in nature, 
nevertheless a number of risk factors and causes have been identified for 
seizures which include5,6 
 Children who required advanced resuscitation at birth 
 NICU admission 
 Family history of seizures 
 Significant head trauma 
 Acute CNS infections in the form of encephalitis, meningitis 
 Presence of neurocutaneous markers such as ash leaf macules, shagreen 
patch,café au lait spots, hemangiomas, adenoma sebaceum etc. 
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 Intracranial lesions in the form of tuberculoma, tumours, 
neurocystecercosis, vascular malformations. 
 Intracranial bleeds secondary to trauma or spontaneous bleeds in cases 
of bleeding disorders. 
 Cerebral malformations. 
 Cerebral infarcts. 
 Electrolyte disturbances. 
 Drug induced or drug withdrawal, poisoning. 
 Reflux seizures precipitated by visual stimuli such as flickering lights, 
patterns, auditory stimuli, somatosensory, proprioceptive, hot water, 
startle, etc. 
Few other conditions such as gastroesophageal reflux and breath holding 
spells can mimic seizures. Certain seizures may also exhibit seizures of 
psychiatric origin. 
CLASSIFICATION AND TYPES OF SEIZURES 
Seizures are basically classified as generalised or focal (previously 
called as partial seizures). Focal seizures are further classified as simple or 
complex based on the impairment of consciousness, 
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A detailed history and clinical examination are usually sufficient to 
determine the type of seizure involved. Investigations like EEG may further aid 
in the diagnosis. In certain special situations such as trauma, intracranial bleed 
andtumours, imaging studies may be required. Determining the seizure type 
may help in starting the appropriate antiepileptic in the patient. The 
antiepileptic to be started also depends on several other characteristics such as 
age of the child, compliance, side effects etc. 
Classification of seizures is also important to explain the prognosis of 
the condition to the parents. For example, certain syndromes such as Dravet 
syndrome is associated with a grave prognosis whereas simple febrile seizures 
are usually associated with a good prognosis. Explaining the prognosis forms 
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an important part of counselling the parents regarding the future risks of 
recurrence ,on how the seizures will impact the quality of life of these children 
and the long term effects . 
Classification of seizures are divided into two main categories- 
according to whether the initial epileptic discharges affect a localised focus in 
the brain (partial seizures) or larger areas in both cerebral hemispheres 
(generalized seizures)7,8,9. 
1. SIMPLE PARTIAL (consciousness retained)  
 Motor  
 Sensory  
 Autonomic  
 Psychic  
2. COMPLEX PARTIAL (consciousness impaired)  
 Simple partial followed by impaired consciousness  
 Consciousness impaired at onset  
 Partial seizures with secondary generalization  
3. GENERALIZED SEIZURES  
 Generalized tonic clonic 
 Tonic 
 Clonic 
 Absence 
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 Myoclonic 
 Atonic 
 Infantile spasms 
PARTIAL SEIZURES:  
A large proportion of childhood seizures up to 40% in some series are 
accounted to partial seizures. 
SIMPLE PARTIAL SEIZURES:  
The most common presentation involves motor activity. These activities 
are characterized by asynchronous tonic or clonic movements and they tend to 
involve the face, neck and extremities10. Versive seizures consisting of head 
turning and conjugate eye movements are also common. Automatism usually is 
not common. Chest discomfort, head ache may occur as a part of aura. The 
only manifestation of seizure may be aura in some cases. An average seizure 
lasts for 10 to 20 sec. The child retains consciousness and may even speak 
during these episodes. No post ictal phenomenon follows the event11.  
Tics may be confused with simple febrile seizures in some cases. Tics 
are characterized by a compulsive urge of activities such as shoulder shrugging, 
eye blinking and facial grimacing and primarily involve the face and shoulder. 
Tics can be voluntarily briefly suppressed but apartial seizure cannot be 
controlled. The varied presentations of partial seizures are as follows- 
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A) WITH MOTOR SYMPTOMS  
Clonic seizures usually involve one side of the body, they usually begin 
from one group of muscles usually the finger flexors and then extends to the 
surrounding groups. The patient remains awake and alert until the seizure 
activity spreads to other half of the cerebral hemisphere leading to  a secondary 
generalized tonic clonic seizure.  
A focal motor seizure may be associated with temporary paralysis of the 
involved side also known as todds paralysis which usually recovers within 24 
hours. If the focal motor seizure activity lasts over a period of weeks, months 
or even years, it is known as Epilepsia partialis continua. In children it may be 
a manifestation of chronic focal encephalitis.  
B) WITH SENSORY SYMPTOMS  
These are usually associated with transient sensation of pins and needles 
or numbness on one side. Olfactory lobe involvement is usually seen as 
sensation of flashing of white lights. Unpleasant odours are a manifestation of 
olfactory seizures. In vertiginous seizures other causes of vertigo including 
benign paroxysmal vertigo, migraine and labrynthitis has to be excluded 
C) WITH AUTONOMIC SYMPTOMS  
Autonomic seizures consist of transient and subtle disturbances. 
Symptoms and signs include pallor, flushing, headache, tachycardia, dilatation 
of the pupils, abdominal pain and loss of bladder control. Autonomic 
symptoms are commonly associated with complex partial seizure.  
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COMPLEX PARTIAL SEIZURES:  
Complex partial seizure may begin with the simple partial seizure with 
or without an aura followed by impaired consciousness. The presence of an 
aura usually indicates focal onset of the seizure. Impaired consciousness in 
infants and children may be difficult to appreciate. Brief periods of blank stare 
or sudden cessation of activity may be noticed. The child is unable to 
communicate or to describe the periods of impaired consciousness in most 
cases.  
Automatism is a common feature of complex partial seizure that occurs 
in around 50% of the cases. Frequency of automatism increases as the age of 
the child increases. They usually develop after the loss of consciousness and 
may persist into the post ictal phase and are not recollected by the child. 
Alimentary automatism includes excessive salivation, chewing ,lip smacking 
etc. These behaviour can be seen in a normal infant also and are usually 
difficult to identify. Gestural automatism includes picking and pulling of 
clothing or bed sheets, rubbing objects, running in a non-directive manner, 
activities performed in a repetitive and often fearful fashion. Spreading of the 
epileptiform discharge during CPS can result in secondary generalization. 
Contralateral versive turning of the head, dystonic posturing and tonic or clonic 
movements of the extremities and face including eye blinking may be noted. 
The entire episode usually lasts around one to two minutes. 
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GENERALIZED SEIZURES:  
Generalized seizures affect the brain as a whole including both cerebral 
hemispheres and often also sub cortical structure with loss of consciousness. 
But in some conditions, such as generalized myoclonic seizure the loss of 
consciousness is so short that it is hardly noticeable. They may be focal in 
onset and then become generalized or may be generalized from the onset. The 
different types of generalised seizures include- 
TONIC CLONIC SEIZURES:  
These seizures are common and may follow a partial seizure or can 
occur de novo. There is a sudden loss of consciousness, the entire body 
musculature undergoes tonic contractions and they rapidly become cyanotic 
due to involvement of the respiratory muscles. The teeth are tightly clenched 
and tongue may be bitten. Excessive salivation, vomiting, loss of bowel and 
bladder control may occur because of autonomic nervous system involvement 
during tonic phase.  
The tonic phase is followed by a clonic phase. At the end of the seizure 
the patient relaxes, respiration becomes normal and the patient passes into post 
ictal depression. When the patient awakens, muscle aches and severe headache 
are noticed. Metabolic disturbances that occur after prolonged seizures include 
hypoxemia, hypercarbia, respiratory acidosis and lactic acidosis. Factors that 
precipitate seizures include low grade fever associated with non-central 
nervous infections, excessive fatigue or emotional stress 
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In status epilepticus repeated tonic clonic seizuresoccur without intervening 
recovery of consciousness. It is classified as  
1. Convulsive status epilepticus- the commonest type in which the patient 
does not recover to a normal alert state between repeated clonic tonic 
attacks  
2. Non- convulsive status epilepticus such as absence status and complex 
partial status in which the clinical presentation is a prolonged twilight 
state.  
3. Epilepsia partialis continua- in which consciousness is preserved. 
ABSENCE SEIZURES:  
TYPICAL ABSENCE SEIZURES:  
It is characterised by a vacant stare and loss of awareness and 
consciousness which is so short lived that the patient does not remember the 
attack but may feel that a short period of time has been lost12. A deep arrest of 
motor activity occurs. They usually occur after 5 years of age, commonly 
observed in girls, not associated with an aura or a post ictal state, rarely lasts 
for greater than thirty seconds. Children may experience countless attacks 
daily. It can easily be missed as they maintain the body tone.  
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ATYPICAL ABSENCE SEIZURES:  
They have an associated motor symptom such as hand fumbling or lip 
smacking or autonomic disturbances including loss of bladder control. 
Sometimes the seizures become almost continuous for hours or days and the 
child passes into a constant state of stupor (petit mal status or spike wave 
stupor)  
MYOCLONIC SEIZURES:  
It consists of sudden shock like brief contractions of the muscle or a 
group of muscles. Myoclonic seizures are distinguished from clonic seizures by 
their non-rhythmic character and lightning fast contractions13. These seizures 
may occur in a multifocal or generalized pattern.  Myoclonic seizures tend to 
be irregular or erratic in nature when repetitive. In certain situations, myoclonic 
seizures may be precipitated by tactile or auditory stimulus. The myoclonic 
contraction EEG is usually associated with a single high-voltage spike which is 
followed by a slow-wave complex. Serious brain dysfunction associated with 
etiologies such as perinatal asphyxia, inborn errors of metabolism, cerebral 
dysgenesis or major brain trauma are characterised by myoclonic jerks.  
Myoclonic seizures are usually associated with a poor long-term 
outcome. Sudden fall usually occurs in older children with generalized 
myoclonic seizures. It is usually seen as a part of a number of epileptic 
syndromes. Certain metabolic states such as high ammonia states in liver 
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failure and hyperuraemia in renal failure can cause myoclonic jerks which 
should not be confused with the ones of epileptic origin. 
ATONIC SEIZURES 
Atonic seizures are also known as drop attacks or akinetic seizures 
characterised be brief episodes of lapses in muscle tone that occur due to 
alteration in the brain function. These episodes are very brief and last for a few 
seconds usually for less than fifteen seconds. They usually begin in childhood 
and progress into adulthood. The seizures as such cause no direct injury but the 
fall episodes can result in injuries. It may be associated with Lennox Gastaut 
syndrome 
INFANTILE SPASMS 
Infantile spasms also known as epileptic spasms, juvenile spasms or a 
part of West syndrome is a rare epilepsy that occurs in children. It is named 
after an English Physician William James West. It is also known by other 
names such as jackknife convulsions, salaam spasms. West syndrome is 
characterised by a triad of infantile spasms, characteristic EEG pattern in the 
form of hypsarrythmia and developemental regression.  
The most common age of presentation is from third month to one year 
of age and it is usually associated with organic brain dysfunction. Typical 
Hypsarrythmia is defined as more or less continuous abnormal EEG with high 
amplitude, irregular and asymmetrical slow wave activity across all leads with 
random sharp waves and spikes producing chaotic pattern. 
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Tuberous Sclerosis is a common cause of infantile spasms. Other causes 
include brain malformations, chromosomal abnormalities, and 
neurodegenerative diseases, perinatal, prenatal, postnatal destructive lesions, 
and brain tumours. 
FEBRILE SEIZURES 
Febrile seizures are those that occur in the absence of CNS infection or 
metabolic disorder with a temperature greater than 100.4F.The most common 
age group involved is from 6 months to 60 months. Previous history of an 
afebrile seizure should be absent. It is broadly classified as a simple or complex 
type.A simple febrile seizure usually has three features 
1. It is a generalised tonic clonic type. Some children have a short period 
of postictal drowsiness but majority of them regain their baseline 
sensorium within a few minutes. 
2. Should not last for more than 15 minutes 
3. Only a single episode should occur within 24 hours. 
A complex febrile seizure is usually focal,lasts for more than 15 minutes 
or haverecurrent episodes within 24 hours. Simple febrile seizures plus is used 
for febrile seizures that recur within 24 hours. Febrile status epilepticus lasts 
for more than 30 minutes. 
Febrile seizures recur in approximately 30% of those who experience 
one febrile seizue,50 %of those who experience two or more episodes and 50% 
of children who experience first episode less than one year of age. There are 
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several factors that determine the risk of recurrence, they are usually classified 
as major and minor risk factors14 
MAJOR RISK FACTORS 
 Age <1 year 
 Duration of fever less than 24 hours 
 Fever 38-39c(100.4-102.2F) 
MINOR RISK FACTORS  
 Family history of febrile seizures 
 Family history of epilepsy 
 Complex febrile seizures 
 Daycare 
 Male gender 
 Lower serum sodium levels at the time of presentation 
Genetic predisposition was suggested by the presence of strong family 
history of febrile seizures in siblings and parents. Genes responsible for febrile 
seizure are FEB 1-7, identified in chromosomes 19p, 8q13-21, 2q24, 18p11.2, 
6q22-24 and 5q14-15bysome linkage analysis. FEB2 gene is responsible for 
coding sodium channel15. In some families, this disease is inherited in an 
autosomal dominant pattern. Febrile seizure may be the manifestation of any 
type of epilepsy. Two most common epilepsy syndromes associated with 
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febrile seizures includes-GEFS +(generalised epilepsy febrile seizure plus) and 
severe myoclonic epilepsy of infancy also known as Dravet syndrome. 
GEFS+ is inherited in an autosomal dominant pattern that has a variable 
phenotypic expression.It usually starts in early childhood and ceases to occur 
by mid childhood. It is characterised by multiple generalised febrile seizures 
that gradually become afebrile seizures which is usually generalised tonic 
clonic type. An epilepsy variant has also been described that has focal instead 
of generalised seizure known as focal febrile seizure plus. 
Dravet syndrome has been characterized by prolonged febrile and non-
febrile seizures within the first year of a child’s life. This disease progresses to 
other seizure types like myoclonic and partial seizures, psychomotor delay, 
and ataxia.It is characterized by cognitive impairment, behavioural disorders, 
and motor deficits. Hyperactivity, impulsiveness, autistic like behaviour are 
commonly included in the behavioural defects. Sleep disorders including 
somnolence and insomnia are also included in Dravet syndrome. The seizures 
worsen as the patient ages. This coupled with the range of severity differing 
between each individual diagnosed and the resistance of these seizures to drugs 
has made the treatment of Dravet syndrome very difficult. 
SEIZURE MIMICS. 
In the new-born it may be difficult to distinguish between true epileptic 
manifestations and normal immature behaviours (e.g., non-nutritive sucking), 
abnormal but non- epilepticbehaviours (e.g., “jitteriness”). Seizure mimics are 
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not stimulus sensitive. Second, passive restraint or repositioning of the infant 
generally abolishes seizure mimics16,17. Third, epileptic seizures are often 
associated with autonomic changes or ocular phenomena. “Jitteriness” (tremor) 
may be distinguished from clonic seizures by the equal amplitude and faster 
equiphasic rhythm, compared to the slower, fast and slow components of clonic 
seizures. Generally, normal non- epileptic behaviours are associated with a 
normal interictal examination. Conversely, abnormal but non- epileptic 
repetitive behaviours often occur in encephalopathic infants with an abnormal 
interictal exam. 
Strongest supportive evidence for true epileptic seizures are a temporal 
association between repetitive clinical events and EEG findings. However, 
using electrographic monitoring to confirm the epileptic nature of suspicious 
clinical events is more difficult in the newborn. This is more difficult when 
clinical seizure events are not accompanied by EEG changes, a situation most 
often seen with subtle seizures and generalized tonic seizures. 
PROGRESSIVE MYOCLONIC EPILEPSY 
They are a group of epilepsies characterised by worsening myoclonic 
and other seizure types and progressive dementia. They are of two types, type 1 
is called Unverrich Lundborg disease caused secondary to cystatin B mutation 
,type 2 is called Lafora body disease usually starts by early adolescence fatal by 
2nd or 3rd decade18.It is usually associated with photosensitivity and  manifests 
as periodic acid Schiff positive Lafora inclusions in muscle or skin biopsy, it is 
caused by mutations in Laforin or Malin gene. Other causes of progressive 
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myoclonic epilepsy include myoclonic epilepsy with ragged red fibres, 
sialidosis type 1,neuronal ceroidlipofuscinosis, juvenile neuropathic gauchers 
disease, dentatorubralpallidoluysian atrophy and juvenile neuroaxonal 
dystrophy. Myoclonic encephalopathy in some congenital disorders such as 
Angelman syndrome consists of difficult to treat myoclonic seizures and at 
times other seizures. 
CLINICAL TESTING AND WORK-UP 
EVALUATIONS 
A detailed history and clinical examination of these children will give an 
important clue to the diagnosis of seizures in most of these cases a few other 
tests are needed for the confirmation and to start the appropriate treatment. The 
parents are usually advised to do a video recording of the seizure activity 
whenever it occurs at home, this will help the physician further in reaching the 
diagnosis. 
The first step in the treatment of seizures is to characterize the patterns 
of brain activity through measurement with various devices. Among these are: 
ELECTROENCEPHALOGRAPHY (EEG): 
This is a non-invasive and painless means of recording the patterns of 
electrical activity of the brain. Electrodes are placed on the scalp which pick up 
and record the electrical activity during periods of seizures19. Certain typical 
patterns such as hypsarrythmia can help in identifying conditions such as 
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infantile spasms. There can be times when a patient may have infantile spasms 
and does not have the hypsarrhythmia pattern due to a lag time between clinical 
symptoms and EEG pattern. In addition, there are several illnesses that can 
mimic epileptic spasms and a long-term video EEG may confirm the diagnosis 
of epileptic spasms.  Therefore, an overnight, long term video EEG monitoring 
is preferable compared to a routine 20-minute EEG study in some cases of 
infantile spasms. 
IMAGING 
COMPUTED TOMOGRAPHY 
Computed Tomography (CT) which involves harnessing X-rays to a 
computer which in turn generates pictures of cross-sections of the brain from 
which any developmental abnormalities of the brain can be made out. CT is 
also very good at showing areas of calcification that might suggest some 
TORCH infections in some cases. However, this does not provide as detailed a 
picture as a MRI20. 
MAGNETIC RESONANCE IMAGING (MRI).  
This radiological technique provides a better view of the posterior fossa 
of the brain. The images are more detailed than a CT and can provide 
information concerning any malformation of the brain structures or other types 
of lesions commonly seen in epileptic spasms21. 
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FUNCTIONAL NEUROIMAGING: 
This includes single photon emission computed tomography (SPECT), 
Positron Emission Tomography(PET), Functional MRI and Magnetic 
Resonance Spectroscopy(MRS). All these are aimed at identifying seizure 
onset. 
Infection as a cause of seizures may be determined by certain blood 
tests, urine tests and lumbar puncture22. 
A Wood’s lamp is used to look for skin lesions which lack skin color in 
order to determine if tuberous sclerosis is a possible diagnosis.ARX and 
CDKL5 genes are associated with X-linked West syndrome that can be 
identified by molecular genetic testing. It is also available for tuberous sclerosis 
complex. Certain conditions such as nonketotic hyperglycemia may require 
CSF samples to test for glycine ,mitochondrial diseases which may require CSF 
to test for lactate. A genetic mutation of STXBP1 has recently been noted in 
patients with Ohtahara’s syndrome as well23. Genetic panels such as Gene Dx 
are available that can test children of a certain age for a variety of genetic 
conditions that are seen in epilepsies such as epileptic spasms. 
TREATABLE METABOLIC EPILEPSIES 
Pyridoxine dependent epilepsy typically begins with increased fetal 
movements in utero and presents as neonatal encephalopathy after birth. It is 
accompanied with gastrointestinal symptoms such as emesis, abdominal 
distension, irritability, recurrent partial motor seizures, myoclonic or 
 20 
generalised tonic clonic seizures. Without pyridoxine they generally progress to 
status epilepticus. Diagnosis is made with elevated levels of alpha aminoadipic 
semialdehyde and pipecolic acid levels in plasma, CSF andurine. Presence of 
homozygous or heterozygous mutation of ALDH7A1 alleles confirms the 
diagnosis. Treatment with 100mg up to max 600mg of pyridoxine stops the 
seizures.  
Pyridoxal phosphate responsive neonatal epileptic encephalopathy 
presents with similar features in the absence of gastrointestinal symptoms. It is 
diagnosed by reduced levels of pyridoxal phosphate and increased levels of 
CSF levodopa and 3-methoxytyrosine, decreased CSF homovanillicacid, 
treatment consists of enteral administration of pyridoxal phosphate. 
MECHANISM OF SEIZURES:  
The exact mechanism of seizures is not known. Several physiological 
factors are responsible for a seizure to occur. To initiate a seizure, there must 
be a group of neurons that cause more of excitatory amino acid production and 
inhibit the inhibitory GABA neurotransmitter24.  
Seizure discharge relies on the involvement of excitatory Glutaminergic 
synapses. Evidence suggests that excitatory aminoacid neuro transmitters 
[Glutamate, Aspartate] play an important role in producing neuronal excitation 
by acting on specific cell receptors25.  
Certain seizures are age dependent. This means that an underdeveloped 
brain is more prone to seizures than the brain of an older infant. This implies 
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that the immature brain is more excitable than the mature brain, reflecting the 
greater influence of excitatory Glutamate containing circuits. The actions of 
GABA, known to be the major inhibitory neurotransmitter, can often 
paradoxically be excitatory in the immature brain. 
The underlying etiology which includes any pathology or pathologic 
process that disturbs the neuronal function and connectivity and makes the 
brain epileptic must be identified. 
The underlying etiologies are diverse which includes from tumours to 
malformations and certain mutations. These mutations can involve voltage 
Gated channels, ligand gated channels or other proteins, for example in Dravet 
syndrome loss of function mutation of SCN1A gene causes decreased 
excitability of the inhibitory GABAergic interneurons leading to increased 
excitability. In human cortical dysplasia the expression of the NR2B subunit of 
the NMDA receptor is amplified leading to excessive depolarising currents 
The role of large molecular cell signalling pathways in epileptogenesis 
namely mammalian target of rapamycin (Mtor),the ras/ERK and the repressor 
element 1 silencing transcription pathways have been found in causing seizures 
The Mtor pathway is responsible in tuberous sclerosis, hemimegalencephaly 
and cortical dysplasia related epilepsy. Thus drugs such as sirolimus and 
everolimus which inhibit the Mtor pathway have been successfully used in 
these conditions .Repressor silencing transcription factors is involved in 
seizures after any neuronal injury. 
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In a seizure focus each neuron has a stereotyped response called 
paroxysmal depolarisation shift that consists of activation of calcium and 
glutamate channels that cause sudden depolarisation and a series of action 
potential at its peak followed by a after polarisation phase that results from 
activation of potassium channels and GABA receptor that activate chloride 
channel. 
In epilepsy related to tumours particularly in those seen in 
oligodendroglioma the voltage gated sodium channels are present on the 
surface of the tumour cells at a higher density than on normal cells and their 
inactivation is impaired by the alkaline ph seen in this condition. 
Prolonged seizures such as febrile and afebrile status epilepticus can 
cause seizure related neuronal injury. A MRI done in these people shows acute 
swelling in the hippocampus and long term hippocampal atrophy with 
sclerosis. There is evidence from surgically resected epileptic tissue that there 
is activation of apoptotic pathways that occurs in these epileptic foci. 
The substantia nigra has an important role in the development of 
generalized seizures in new-borns. It has been proposed that the functional 
immaturity of the substantia nigra may have a role in the increased seizure 
susceptibility of the immature brain26.  
Additionally, the GABA sensitive substantia nigra alsoplay a part in 
preventing seizures. It is now known that substantia nigra outflow tracts 
modulate and regulate seizure dissemination but are not responsible for the 
onset of seizures. 
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The presumed mechanism of damage in HS is discharge 
of glutamate during the epileptic attack and the most frequent site of damage is 
the CA1 sector of the hippocampus. This area is also vulnerable to hypoxia 
which also initiates an excitotoxic cascade. However, epileptic brain damage is 
not limited to the hippocampus. Intractable epilepsy and status epilepticus also 
cause neuronal loss in the cerebral cortex, thalamus, and cerebellum (Purkinje 
cells). 
TREATMENT OF SEIZURES 
After a first seizure if the risk of the seizure recurring is low such as 
normal neurodevelopmental status, normal EEG, MRI then treatment is usually 
not indicated. Treatment is started if the patient has an abnormal neurological 
examination, development, abnormal EEG, MRI, family history of seizures, or 
other risk factors. The decision is based on individualized bases and is 
discussed with the family 
COUNSELLING 
Treatment may require a multidisciplinary approach involving a team of 
specialists. Paediatricians, neurologists, surgeons, and/or other health care 
professionals may need to systematically and comprehensively plan an affected 
child’s treatment. An important part in the treatment of patients is counselling 
which includes explaining the condition to the parents, the nature of the 
disease, the prognosis of the patient. Restrictions on activities such as 
swimming or driving is usually necessary 
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Epilepsy does carry an increased risk of mortality and of sudden unexpected 
death. This is mostly related to conditions associated with the underlying 
epilepsy or poor seizure control and to poor compliance with prescribed 
therapies. 
ANTIEPILEPTICS 
AEDs reduce the excitability by interfering with several channels such 
as sodium, potassium or calcium ion channels, they ultimately act by reducing 
the excitatory pathway or by enhancing the inhibitory pathway. Most of the 
antiepileptics have multiple mechanisms of action27. Voltage gated sodium 
channels are blocked by medications such as felbamate, valproate28, 
topiramate, carbamazepine, oxcarbamazepine, lamotrigine, phenytoin, 
rufinamide, lacosamide, andzonisamide.T type calcium channels are found in 
the thalamus and are blocked by valproate, zonisamide29, ethosuximide. 
Voltage gated calcium channels are inhibited by gabapentin, pregabalin, 
lamotrigine, felbamate. Ntype calcium channels are inhibited by levetiracetam 
.Novel drugs Ezogabine/retigabine opens KCNQ/Kv7 voltage gated potassium 
channels. 
The older and most commonly used medications in the treatment of 
childhood epilepsy includes phenobarbitone, phenytoin, sodium valproate and 
carbamazepine. Phenytoin and phenobarbitone, previously drugs of first choice 
for most seizure types before the advent of carbamazepine and sodium 
valproate, are not considered first line anymore due to the long-term side 
effects associated with most of them. However, in certain situations they may 
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still be effective, but only when other drugs have ‘failed’ and where seizure 
control is the major  if not only  priority. Further, they still remain the first-
line treatment in the acute management of neonatal seizures in view of their 
parenteral availability and safety profile.  
The benzodiazepines are also effective AEDs, not only for generalised, 
but also for focal seizures and some epilepsy syndromes. Their use may be 
restricted by acute toxicity, and the development of tolerance or tachyphylaxis. 
For the above reasons, benzodiazepines are rarely, if ever, the initial AED, 
other than for infants and children with myoclonic seizures as the only seizure 
type, when low-dose clonazepam or clobazam may be used as monotherapy. 
Nitrazepam may be effective in suppressing infantile spasms, and particularly 
when these have arisen as a consequence of neonatal hypoxic-ischaemic 
encephalopathy. Clobazam is also often very effective as an add-on treatment 
for treating partial seizures (with or without secondary generalised tonic-clonic 
seizures), atypical absences, electrical status epilepticus of slow-wave sleep 
(ESESS) and catamenial seizures. It is also used as intermittent prophylaxis in 
febrile seizures. 
Sodium valproate was approved for use is U.S in 1978. It is a simple 
branched chain carboxylic acid (N-dipropyl acetic acid).Mechanism of action: 
The action appears to be mediated by a prolonged recovery of voltage activated 
sodium channels from inactivation. In neurons isolated from distinct region, 
nodose ganglion, valproate reduces the low threshold (T) calcium current. It 
also increases the amount of GABA that can be recovered from the brain after 
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the drug is administered to animals. In vitro, valproate can stimulate the 
activity of the GABA synthetic enzyme, glumatic acid decarboxylase and 
inhibit GABA degredative enzymes, GABA transaminase and succinct semi 
aldehyle dehydrogenase  
Pharmacokinetic properties: 
 Absorbed rapidly and completely after oral administration. 
 Peak concentration in plasma is observed within 1-4hr, this can be 
delayed for several hrs if the drug is administered in enteric coated 
tablets or is ingested with meals. 90% bound to protein. The vast 
majority of valproate (95%) undergoes hepatic metabolism, with less 
than 5% excreted unchanged 
Toxicity: 
The most common side effects are transient GIT symptoms in about 
60% of patients. Effects on CNS include sedation, ataxia and tremor. It also 
causes rash, alopecia, stimulation of appetite. It has also several effects on 
hepatic functions, increases liver enzymes in 40% of patients, rare complication 
is fulminant hepatitis , acute pancreatitis and hyperammonemia. 
Carbamazepine was initially approved in the U.S for use as an anti-
seizure agent in 1974. It is now considered to be a primary drug for the 
treatment of partial and tonic-clonic seizures, chemically it is related to the 
tricyclic anti-depressants.CBZ have been found to produce therapeutic 
responses in manic depressive patients.CBZ limits the repetitive firing of action 
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potentials evoked by a sustained depolarization CBZ is absorbed slowly and 
erratically after oral administration. Peak concentration in plasma is usually 
observed 4 - 8 hrs after oral ingestion, but may be delayed as much as 24 hr, 
specially following the administration of a large dose. It is distributed rapidly 
to all tissues. Binding to plasma protein occurs to the extent of about 75%. The 
predominant pathway of metabolism in human being involves conversion to the 
10,11-epoxide. CBZ induces CYP2C and CYP3A and also UDP-
glucouronosyltransferse. Thus enhancing the metabolism of drug degraded by 
these enzymes. 
Phenobarbitone is a an age old anticonvulsant that acts through its action 
on GABA receptors, phenobarbitone increases flux of chloride ions into the 
neuron which decreases excitability. Direct blockade of excitatory glutamate 
signaling is also believed to contribute to the hypnotic/anticonvulsant effect 
that is observed with the barbiturates. Sedation and hypnosis are the principal 
side effects (occasionally, they are also the intended effects) of phenobaritone. 
CNSeffects, such as dizziness, nystagmus and ataxia, are also common. In 
elderly patients, it may cause excitement and confusion, while in children, it 
may result in paradoxical hyperactivity. Phenobarbital is a cytochrome 
P450 hepatic enzyme inducer. Drugs that are metabolized by the CYP450 
enzyme system will have decreased effectiveness because of faster clearance 
from the system. 
Ethosuximide has traditionally been used for childhood absence 
epilepsy, but can also be effective where spike-wave activity is prominent, such 
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as atypical absence of Lennox-Gastaut syndrome or continuous spike-wave of 
slow sleep. Numerous AEDs are licensed for use as adjunctive or as 
monotherapy in a range of seizure types and epilepsy syndromes vigabatrin, 
lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, 
pregabalin, zonisamide, rufinamide, lacosamide, eslicarbazepine and, most 
recently, perampanel30. Lamotrigine has a monotherapy licence for patients 
aged 12 years and older but as adjunctive therapy from two years. Vigabatrin is 
used as monotherapy in children with infantile spasms in west syndrome. 
Topiramate is now used in children above six years. Pregabalin, zonisamide 
and lacosamide have licences for use as adjunctive therapy in people aged 18 
years and above. Perampanel has a license for adjunctive therapy of focal 
seizures over the age of 12 years. Of these new AEDs, lamotrigine, topiramate 
and levetiracetam would appear to have the broadest spectrum of action, being 
effective against many generalised and focal seizure types, and relatively free 
of serious side effects, other than lamotrigine that can produce allergic or 
idiosyncratic rash, that rarely develops into Stevens-Johnson syndrome. 
Lamotrigine can be effective in controlling typical absence seizures but not as 
effective in the treatment of myoclonic seizures. Levetiracetam also has a broad 
spectrum of action against different seizure types and has a very good safety 
profile with features of hostility seen in some cases. 
Vigabatrin is also a very effective drug in the treatment of infantile 
spasms to the point where it is recognised as a drug of first choice particularly 
when the underlying cause is tuberous sclerosis. Vigabatrin is also useful for 
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focal seizures, with or without secondary generalisation, and appears to be 
particularly effective in children who have an underlying structural lesion such 
as focal cortical dysplasia or even low-grade tumours31. However, the drug 
may exacerbate myoclonic and typical absence seizures. The drug also appears 
to have a relatively impressive short-term safety profile. Rarely, however, 
behavioural effects may occur, such as agitation or a change in muscle tone and 
an increased appetite; these effects are transient and resolve once the dose is 
reduced or the drug withdrawn. However, the peripheral visual field 
constriction was reported to occur in up to 40% of adult patients treated with 
vigabatrin. At the current time, visual field defects have been reported in 
children but it is not known whether children are likely to be at a higher or 
lower risk of developing a visual field defect and also whether any visual field 
constriction is more or less likely to be reversible than in adults. The drug is 
known to cause a number of does acute and predominantly dose-related side 
effects, especially on the central nervous system. These include symptoms such 
as dizziness, drowsiness, irritability, fatigue, word-finding difficulties/mild 
cognitive impairment and, rarely, acute depressive and psychotic illness. These 
can be minimised by introducing the drug at a lower dose. Paraesthesia, 
glaucoma and renal calculi have also been reported but predominantly seen in 
adults 
Like vigabatrin, tiagabine also has a direct effect on GABA-ergic 
neurotransmission (and GABA levels) and although it is theoretically possible 
that tiagabine might also affect visual field function, but clinical trials suggest 
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that this drug does not produce the same visual field defect that is seen with 
vigabatrin. A number of anecdotal reports have suggested that the drug may 
precipitate non-convulsive status epilepticus.  
Oxcarbazepine, structurally similar to carbamazepine, was licensed for 
use in the UK in 2002. Its spectrum of action is almost identical to 
carbamazepine, but as it is not metabolised to 11 epoxide metabolite it has 
relatively fewer side effects. However, hyponatraemia is reported to occur 
more frequently with oxcarbazepine – although rarely with any significant 
clinical effects. The drug is available as a standard release tablet and liquid 
suspension. It can safely be given to children who had developed an 
idiosyncratic rash due to carbamazepine. Like carbamazepine, oxcarbazepine 
may exacerbate the absence and myoclonic seizures that occur in the 
generalised epilepsies 
Rufinamide is licensed in the UK for treatment of seizures associated 
with Lennox-Gastaut syndrome. Acetazolamide, a diuretic and carbonic 
anhydrase inhibitor, is considered by many to be a useful add-on drug (usually 
in combination with carbamazepine) in treating focal seizure. Biotin should 
also be used in infants and young children with refractory seizures after 
checking the biotidinase levels. Folinic acid should also be used for any infant 
with neonatal-onset seizures that have been resistant to both conventional 
antiepileptic medication and pyridoxine where no other identifiable cause has 
been found for the epilepsy. Steroids, given either as prednisolone or less 
commonly hydrocortisone or adrenocorticotrophic hormone, are frequently 
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used in treating different seizure types or epilepsy syndromes, including acute 
epileptic encephalopathies. The mechanism of action of steroids is unclear but 
they may be very effective, particularly in the following situations:  
 Infantile spasms (West syndrome)  
 Continuous spike-wave in slow sleep (CSWSS), also called electrical 
status epilepticus of slow sleep (ESESS) 
 Dravet syndrome 32 
 Lennox-Gastaut syndrome, particularly in non-convulsive (atypical 
absence) status33 
 Other, rare epileptic encephalopathies. 
Intravenous immunoglobulins have been used with varying (usually 
very limited), success in intractable epilepsies including children with both the 
West syndrome and Lennox-Gastautsyndromes. There are marked variations in 
the frequency of courses, duration of treatment and doses of this particular 
therapy and there is as yet no established or universally accepted mechanism of 
action.  
Drug choice in childhood epilepsy should, wherever possible be 
evidence based as in older individuals. Another well-constructed randomised 
crossover study demonstrated stiripentol, a cytochrome P450 inhibitor, to be 
significantly more effective than placebo when added to sodium valproate and 
clobazam however, this drug may be associated with significant somnolence as 
well as loss of appetite. These must be effective (preferably with a broad 
spectrum of action against a wide range of seizure types), safe and be available 
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in child-friendly formulation. However, while the advent of the new AEDs 
should be welcomed, it is important to use the older, ‘conventional’ AEDs 
appropriately and initially, particularly in view of the limited data on both 
monotherapy efficacy and longterm safety for newer compounds. The classic 
example is the use of carbamazepine or oxcarbazepine for juvenile-onset 
absence or juvenile myoclonic epilepsy, when it is known to exacerbate both 
the myoclonic and absence seizures which characterise these syndromes. 
Further, when initiating teenage girls on medication that may need to be 
lifelong, the possibility of pregnancy and the effects of AEDs in utero need to 
be taken into consideration and individuals counselled accordingly; this is 
particularly important when discussing and prescribing sodium valproate. 
Thus while selecting anticonvulsants the following points have to be 
taken into consideration34. 
 The choice of AED in treating the childhood epilepsies will be 
determined by the epilepsy syndrome (and therefore the specific 
seizures that help to define the syndrome), safety profile and, to a 
slightly lesser extent, its ease of use (formulation and dosing regimen). 
 Sodium valproate appears to remain the most effective AED in treating 
generalised seizures. 
 Lamotrigine, closely followed by carbamazepine or oxcarbazepine, 
appears to be the most effective and ‘best tolerated’ AED in treating 
focal seizures . 
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 The major benefit of the newer AEDs seems to be their lower (and also 
milder) incidence of adverse side effects although there are some 
exceptions . 
 It is important to be aware of drugs that may exacerbate some seizure 
types. 
 The temptation should be strongly resisted to indulge in polypharmacy, 
it is always easier to add another drug than to withdraw one. There are 
no convincing data that the simultaneous use of three AEDs results in 
better seizure control than two drugs. ‘Polypharmacy’ increases the risk 
and incidence of adverse side effects; in addition, three drugs, in causing 
drowsiness and disturbing sleep patterns, may paradoxically cause a 
deterioration in seizure control, as well as an increase in adverse side 
effects.  
Drug of choice for various seizure types include 
 Focal seizures- Oxcarbazepine and carbamazepine 
 Absence seizures- Ethosuximide and sodium valproate 
 Juvenile myoclonic epilepsy-Sodium valproate and lamotrigine 
 Lennox gastaut syndrome-Clobazam, valproate, topiramate, lamotrigine 
,and newer drug rufinamide 
 Infantile spasm- Adrenocorticotrophic hormones,prednisolone and 
vigabatrin. 
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Surgical Treatment: 
Surgical treatment can be an option for epilepsy when an underlying 
brain abnormality, such as a benign tumour oran area of scar tissue (e.g. 
hippocampal sclerosis) can be identified. Also it is offered to patients when 
their epilepsy has not been controlled by adequate attempts with multiple 
medications35 
Other treatment: 
Ketogenic diets may occasionally be effective in controlling some types 
of epilepsy; although the mechanism behind the effect is not fully understood, 
shifting of pH towards a metabolic acidosis and alteration of brain metabolism 
may be involved. Ketogenic diets are high in fat and extremely low in 
carbohydrates, with intake of fluids often limited36. 
THYROID GLAND 
Chemistry of Thyroid Hormones 
Thyroid hormones are derivatives of the amino acid tyrosine covalently 
bound to iodine. The two principal thyroid hormones are37: 
 thyroxine (also known as T4 or L-3,5,3',5'-tetraiodothyronine) 
 triiodotyronine (T3 or L-3,5,3'-triiodothyronine). 
The thyroid hormones are basically two tyrosines that are linked 
together with the critical addition of iodine at three or five positions on the 
aromatic rings. The numbering and position of the iodine is important. A 
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number of other iodinated molecules are generated that have little or no 
biological activity; so called "reverseT3" (3,3',5'-T3) is such an example. 
Vast majority of the thyroid hormone secreted from the thyroid gland is 
T4, but T3 is the considerably more active form of the hormone. Although 
some amount of T3 is also secreted, the majority of the T3 is derived by 
deiodination of T4 in peripheral tissues, especially liver and kidney. 
Deiodination of T4 also gives reverse T3, a molecule with no known metabolic 
activity. Thyroid hormones are insoluble in water, and more than99% of the T3 
and T4 circulating in blood are bound to carrier proteins. The principle carrier 
protein of thyroid hormones is thyroxine-binding globulin, a glycoprotein 
synthesized in the liver as a 54 Kdalton protein. It has the highest affinity to T3 
and T4 and present in the lowest concentration. Despite the low concentration 
it carries the majority of T4 in the bloodstream. Two other carriers of transport 
are transthyrein and albumin. Carrier proteins allow maintenance of a stable 
pool of thyroid hormones from which the active, free hormones are released for 
uptake by target cells38. 
SYNTHESIS AND SECRETION OF THYROID HORMONES 
Thyroid hormones are synthesized by mechanisms fundamentally 
different from those seen in other endocrine systems. Thyroid follicles serve as 
both factory and warehouse for production of thyroid hormones. 
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The entire synthetic process occurs in three basic steps 
 Production and accumulation of the raw materials . 
 Fabrication or synthesis of the hormones on a backbone or scaffold of 
precursor . 
 Release of the free hormones from the scaffold and secretion into blood 
. 
The process for making thyroid hormones calls for two principle raw materials: 
 Tyrosines are provided from a large glycoprotein scaffold called 
thyroglobulin, which is synthesized by thyroid epithelial cells and 
secreted into the lumen of the follicle – colloid which is essentially 
apool of thyroglobulin. A molecule of thyroglobulin contains 
134tyrosines, although only a handful of these are actually used 
tosynthesize T4 and T3. 
 Iodine, or more accurately iodide (I-), is avidly taken up from blood by 
thyroid epithelial cells, which have on their outer plasma membrane a 
sodium-iodide symporter or "iodine trap". Once inside the cell, iodide is 
transported into the lumen of the follicle along with thyroglobulin. 
Fabrication of thyroid hormones is conducted by the enzyme thyroid 
peroxidase, an integral membrane protein present in the apical(colloid-
facing) plasma membrane of thyroid epithelial cells. Thyroidperoxidase 
catalyzes two sequential reactions: 
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1. Iodination of tyrosines on thyroglobulin (also known 
as"organification of iodide"). 
2. Synthesis of thyroxine or triiodothyronine from two 
iodotyrosines(also known as “coupling of iodotyrosines”) 
CONTROL OF THYROID HORMONE SYNTHESIS AND SECRETION 
Each of the processes described above appears to be stimulated by 
thyroid-stimulating hormone from the anterior pituitary gland. Binding of TSH 
to its receptors on thyroid epithelial cells stimulates synthesis ofthe iodine 
transporter, thyroid peroxidase and thyroglobulin. The magnitude of the TSH 
signal also sets the rate of endocytosis of colloid - high concentrations of TSH 
lead to faster rates of endocytosis, and hence, thyroid hormone release into the 
circulation. Conversely, when TSH levels are low, rates of thyroid hormone 
synthesis and release diminish. 
MECHANISM OF ACTION AND PHYSIOLOGIC EFFECTS OFTHYROID 
HORMONES IN THE BODY 
Receptors for thyroid hormones are intracellular DNA-binding proteins 
that function as hormone-responsive transcription factors, very similar 
conceptually to the receptors for steroid hormones. 
Thyroid hormones enter cells through membrane transporter proteins. A 
number of plasma membrane transporters have been identified, some of which 
require ATP hydrolysis; the relative importance of different carrier systems is 
not yet clear and may differ among tissues. Once inside the nucleus, the 
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hormone binds its receptor, and the hormone-receptor complex interacts with 
specific sequences of DNA in the promoters of responsive genes. The effect of 
the hormonereceptor complex binding to DNA is to modulate gene expression, 
either by stimulating or inhibiting transcription of specific genes. 
PHYSIOLOGIC EFFECTS OF THYROID HORMONES 
It is likely that all cells in the body are targets for thyroid hormones. 
While not strictly necessary for life, thyroid hormones have profound effects on 
many "big time" physiologic processes, such as development, growth and 
metabolism.  
Metabolism: Thyroid hormones stimulate diverse metabolic activities of 
most tissues, leading to an increase in basal metabolic rate. One consequence of 
this activity is to increase body heat production, which seems to result, at least 
in part, from increased oxygen consumption and rates of ATP hydrolysis.  A 
few examples of specific metabolic effects of thyroid hormones include: 
 Lipid metabolism: Increased thyroid hormone levels stimulate fat 
mobilization, leading to increased concentrations of fatty acids in 
plasma. They also enhance oxidation of fatty acids in many tissues. 
Finally, plasma concentrations of cholesterol and triglycerides are 
inversely correlated with thyroid hormone levels. One diagnostic 
indication of hypothyroidism is increased blood cholesterol 
concentration. 
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 Carbohydrate metabolism: Thyroid hormones stimulate almost all 
aspects of carbohydrate metabolism, including enhancement of insulin-
dependent entry of glucose into cells and increased gluconeogenesis and 
glycogenolysis to generate free glucose. 
Growth: Thyroid hormones are clearly necessary for normal growth in 
children, as evidenced by the growth-retardation observed in thyroid 
deficiency. Not surprisingly, the growth-promoting effect of thyroid hormones 
is intimately intertwined with that of growth hormone, a clear indication that 
complex physiologic processes like growth depend upon multiple endocrine 
controls. 
Development: A classical experiment in endocrinology was the 
demonstration that tadpoles deprived of thyroid hormone failed to undergo 
metamorphosis into frogs. Of critical importance in mammals is the fact that 
normal levels of thyroid hormone are essential to the development of the fetal 
and neonatal brain. It has been well documented that one of the various 
reversible causes of mental retardation is hypothyroidism provided the 
condition is diagnosed early during the newborn period and thyroxine 
supplementation is started immediately. 
Other Effects: As mentioned above, there do not seem to be organs and 
tissues that are not affected by thyroid hormones. A few additional, well-
documented effects of thyroid hormones include: 
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 Cardiovascular system: Thyroid hormones increases heart rate,cardiac 
contractility and cardiac output. They also promote vasodilation, which 
leads to enhanced blood flow to many organs. 
 Central nervous system: Both decreased and increased concentrations of 
thyroid hormones lead to alterations in mental state. Too little thyroid 
hormone, and the individual tends to feel mentally sluggish, while too 
much induces anxiety and nervousness. 
 Reproductive system: Normal reproductive behaviour and physiology is 
dependent on having essentially normal levels of thyroid hormone. 
Hypothyroidism in particular is commonly associated with infertility. 
THYROID DISEASE STATES 
Disease is associated with both inadequate production and over 
production of thyroid hormones. Both types of disease are relatively common 
afflictions of children. Hypothyroidism is the result from any condition that 
results in thyroid hormone deficiency. Two well-known examples include 
 Iodine deficiency: Iodide is absolutely necessary for production of 
thyroid hormones; without adequate iodine intake, thyroidhormones 
cannot be synthesized. Historically, this problem was seen particularly 
in areas with iodine-deficient soils, and frank iodine deficiency has been 
virtually eliminated by iodine supplementation of salt. 
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 Primary thyroid disease: Inflammatory diseases of the thyroid that 
destroy parts of the gland are clearly an important cause of 
hypothyroidism39. 
Congenital hypothyroidism: sporadic and familial forms . In many cases 
the deficiency occurs and manifestations may develop in the early weeks of life 
or may be delayed for months 
Clinical features: Large anterior fontanels, coarse faces, umbilical 
hernia, lethargy and irritability, large tongue, coarse voice, retarded 
development and growth. 
Neonatal Period Early Symptoms: 
1. Prolonged gestation with large bulk weight 
2. Persistent jaundice 
3. Temperature instability. 
4. Delayed initial bowel opening for >24hrs. 
5. Oedema 
6. Hypo activity and poor feeding 
Treatment should begin immediately after the diagnosis is established. 
Recommended dosage of synthetic thyroxine is 10 – 15 microgram /kg for the 
newborn and less thereafter. 
Common symptoms of hypothyroidism arising after early childhood 
include lethargy, fatigue, cold-intolerance, weakness, hairloss, mental changes, 
cognitive impairment. If these signs are severe, the clinical condition is called 
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myxedema. In the case of iodide deficiency, the thyroid becomes inordinately 
large and is called a goitre. The most severe and devastating form of 
hypothyroidism is seen in young children with congenital thyroid deficiency. If 
that condition is not corrected by supplemental therapy soon after birth, the 
child will suffer from cretinism, a form of irreversible growth and mental 
retardation. Most cases of hypothyroidism are readily treated by oral 
administration of synthetic thyroid hormone. In times past, consumption of 
dessicated animal thyroid gland was used for the same purpose. 
EFFECTS OF ANTI-EPILEPTIC DRUGS ON THYROID FUNCTION: 
A number of side effects of antiepileptics on the endocrine system have 
been reported. In the case of thyroid hormones, a number of important 
metabolic pathways interact to balance synthesis, bioactivation, deactivation. 
Because drugs, industrial chemicals and chemicals of environmental 
importance can increase thyroid hormone metabolism, it is important to 
consider the impact these compounds have on thyroid hormone and thyroid 
gland. 
Antiepileptic drugs change circulating hormones concentration and also 
pituitary responsiveness to various stimuli40. The level at which the 
antiepileptic drugs affect the endocrine system is not certain. The influence of 
phenytoin and carbamazepine on the thyroid hormone has both interested and 
confused clinicians and investigators for more than three decades41.The first 
study about the effects of antiepileptic drugs on thyroid gland was made in 
1961 by Oppenheimer et al. They found that phenytoin treatment reduces 
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thyroid hormone concentration in patients with epilepsy. Moreover, since 1970 
it has been obvious that carbamazepine therapy also changes the thyroid 
hormones balance in epileptic patients. Since then several studies have been 
reported about the toxic effects of antiepileptic drugs on thyroid glands. It was 
found that some antiepileptic drugs decrease thyroid function but does not 
change the euthyroid state42. 
Concerning mechanisms by which anti-epileptic drugs affect the thyroid 
hormones concentrations, Oppenhimier et al reported that serum protein bound 
iodine concentration was significantly decreased in 30 patients treated with 
phenytoin. Another hypothesis is that at therapeutic concentrations these drugs 
displace thyroid hormone from their serum binding protein43.Generally, 
Phenobarbital, phenytoin and carbamazepine are called as “enzyme-inducing 
antiepileptic drugs” because of their activating effect on hepatic microsomal 
enzyme system. This enzyme inducing property may be responsible for the 
increased metabolism of thyroid hormones leading to alterations in thyroid 
hormone levels. One article suggests that carbamazapine may also have direct 
inhibitory effects on iodide uptake and hormone synthesis in the thyroid44.The 
high levels of serum basal thyroid-stimulating hormone observed in patients 
receiving valproate monotherapy and patients receiving carbamazepine-
valproate combination therapy may be because of the GABA stimulating 
properties of valproate, because gammaaminobutyric acid inhibits the release 
of somatostatin, and somatostatin inhibits thyroid stimulating hormone 
secretion45.  
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REVIEW OF LITERATURE 
A number of studies have been conducted to study the effect of 
antiepileptics on thyroid hormones. Alberto Verrotiet all conducted a study in 
the university of neuropsychiatry, university of Bolonga on thyroid hormones 
in children with epilepsy on long term administration of carbamazepine and 
sodium valproate. A prospective study was conducted in 32 newly diagnosed 
children .Serum TSH,freet3,freet4 were evaluated at baseline ,3 ,6 ,12 months, 
it was found that freet4 values were reduced in carbamazepine group and 
normal in sodium valproate group.TSH and freet3 remained unaffected in both 
the groups. 
EirisPufialet all conducted a study in Spain to study the incidence of 
subclinical hypothyroidism in children taking carbamazepine, sodium valproate 
and phenobarbitone. Serum t3,t4 and TSH in 148 healthy and 141 children on 
anticonvulsants were measured. It was found that 8.2% of children on 
carbamazepine had a TSH values higher than normal.26% of children treated 
with sodium valproate had an elevated TSH, thus the incidence of subclinical 
hypothyroidism was higher in patients on sodium valproate therapy. 
Korkmaz  et all conducted a study at Department of Pediatric Neurology 
Children’s Hospital, Izmir, Turkey .The study aimed at observing the effects of 
phenobarbitone, valproate, carbamazepine, oxcarbazepine, and levetiracetam 
monotherapy on thyroid function in daily clinical practice during a 12-month 
treatment period. A total of 223 children (103 females and 120 males) with new 
onset and controlled epilepsy treated with valproate (n = 129), phenobarbital (n 
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= 33), carbamazepine (n = 36), oxcarbazepine (n = 14), levetiracetam (n = 11) 
were included in the study. Serum free thyroxine (fT4) and thyroid-stimulating 
hormone (TSH) levels were measured before and at first, sixth and twelfth 
months of therapy. They found out thatat baseline, average fT4 and TSH 
concentrations were not different between the drug groups. Valproate-treated 
patients had decreased fT4 and increased TSH levels at months 1, 6, and 12. 
The Carbamazepine-treated patients had decreased fT4 levels at months 1, 6, 
and 12 and increased TSH levels at months 1, and 6. Phenobarbital-treated 
patients had decreased fT4 levels at months 1, and 6, and increased TSH levels 
at months 6 and 12. The Oxcarbazepine-treated patients had decreased fT4 
levels at month 1. The Levetiracetam-treated patients showed no significant 
change of fT4 and TSH at any times. The frequency of subclinical 
hypothyroidism at the end of one year was 28% in valproate, 21.4% in 
oxcarbazepine, 18.2% in phenobarbital, 13.9% in carbamazepine, and 0% in 
levetiracetam groups. Conclusion from the above data suggest that all 
antiepileptic drugs studied except levetiracetam had varying degrees of 
deleterious effects on thyroid function. 
Yaseretall conducted a study insouth valley university qeuna – 
Egyptonthyroid hormone level changes in epileptic children on valproate mono 
therapy. Around twenty children on valproate monotherapy for a minimum of 
three months and ten apparently normal children were selected. All patients and 
controls were assessed thyroid hormones, liver function and some hematologic 
parameters. The study concluded that the mean serum levels of thyroid 
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hormones in patients were not statistically significant different from those of 
the controls (p>0.05).  
Manuel et all studied the evolution of subclinical hypothyroidism in 
children on anticonvulsants.TSH ,freet3 and freet4 levels were measured in 
children on anticonvulsants monotherapy during treatment and three months 
following the stopping of these drugs, subclinical hypothyroidism was 
observed in the children receiving sodium valproate and carbamazepine 
group.A complete return to baseline was observed after a period of three 
months of drug discontinuation attributing the alterations in thyroid hormone 
levels to the anticonvulsants. 
Hosny M.A.et all conducted a study at Al-Azhar University Egypt on 
Subclinical Hypothyroidism and Dyslipidemia in Upper Egyptian Epileptic 
Children on Carbamazepine Therapy. Thirty epileptic children on 
carbamazepine and age matched controls were selected. Patient group was then 
subdivided into two subgroups according to the duration of treatment. All 
patients and controls were subjected to assessment of serum thyroid hormones 
and lipid profile. The mean serum levels of freet4in patient group was 
significantly lower than that of control group (p=0.01 & 0.004 
respectively),while the mean serum levels of total and free T3 and TSH were 
not significantly different (p>0.05).The mean serum levels of cholesterol, 
triglycerides and LDL in patients with prolonged durationof therapy was 
significantly higher than those patients with shorter duration of therapy.  
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AIMS AND OBJECTIVES 
To study the thyroid profile in children on anticonvulsant monotherapy 
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METHODOLOGY 
Study design: Case control 
Study population: 150 children on anticonvulsant monotherapy meeting the 
inclusion criteria as cases, 150 age and sex matched children as controls. 
Place of study: Children attending outpatient department and admitted in the 
medical wards  at institute of child health. 
Study period: January 2017-september 2017 
Inclusion criteria: Children attending op and admitted in medical wards on 
anticonvulsant monotherapy. 
Exclusion criteria:  
 Children with progressive neurological,thyroid or other metabolic 
disease. 
 Those who have received any drug in the past 6 months that could effect 
thyroid function. 
 Family history of thyroid dysfunction or other endocrine problems. 
 Poor complaince to medications 
Study procedure: After getting informed consent from the parents of cases 
and controls, they are subjected to detailed history and clinical examination and 
the findings are entered in the proforma. 
Thyroid levels are then measured. For this 2ml of blood was collected 
into test tubes through venipuncture under strict aseptic precautions. Serum is 
separated from cells by centrifugation. The sample is then subjected to ECLIA 
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(Electro ChemiluminescentImmuno Assay ) to measure freeT3,freeT4 and TSH 
levels.the normal range of thyroid levels are as follows- 
TSH (micro IU/ml) 
<1 year-0.72-8.35 
1-6 years-0.73-5.97 
7-12 years-0.60-4.84 
freeT3(ng/dl) 
<1 year-0.89-1.99 
1-6 years-0.96-1.77 
7-12 years-0.97-1.67 
freeT4(pg/ml) 
<1 year-1.95-5.83 
1-6 years-2.41-5.50 
7-12 years-2.53-5.22 
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STUDY JUSTIFICATION 
Many AEDs may alter thyroid levels at the level of 
biosynthesis,release,transport and metabolism. 
Studies to determine the prevalence and risk factors for thyroid 
dysfunction are needed. 
Periodic screening in children on AEDs is necessary to identify early 
subclinical hypothyroidism 5-20% of children with clinical hypothyroidism 
have shown to progress to overt hypothyroidism by adolescent especially those 
associated with goitre ,female sex,anti TPO antibodies.Children with 
subclinical hypothyroidism when treated have shown improvement in 
neurocognition and growth velocity. 
STATISTICAL ANALYSIS: 
Statistical analysis of data will be performed by statistical software 
SPSS. Outcome variables will be categorized as normal or abnormal(high or 
low) and their prevalence will be expressed as percentage and p value of <0.05 
will be considered significant. 
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OBSERVATION AND RESULTS 
1) Age distribution 
 GROUP Total 
CASE CONTROL 
Age 
<1 
YEAR 
Count 15 14 29 
% within GROUP 10.0% 9.3% 9.7% 
1-3 
YEARS 
Count 53 49 102 
% within GROUP 35.3% 32.7% 34.0% 
3-6 
YEARS 
Count 51 47 98 
% within GROUP 34.0% 31.3% 32.7% 
6-10 
YEARS 
Count 23 24 47 
% within GROUP 15.3% 16.0% 15.7% 
10-12 
YEARS 
Count 8 16 24 
% within GROUP 5.3% 10.7% 8.0% 
Total 
Count 150 150 300 
% within GROUP 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.043 p=0.551 
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In this study a total of 150 cases and controls were selected .Among the 
cases the distribution among age group were<1 year(10%),1-3 years(35.3%),3-
6 years(34%),6-10 years(15.3%),10-12 years(5.3%).Among the controls the 
distribution were<1year(9.3%),1-3 years(32.7%),3-6 years(31.3%),6-10 
years(16%),10-12 years(10.7%). 
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2) Sex distribution 
 GROUP Total 
CASE CONTROL 
sex 
MALE 
Count 101 96 197 
% within GROUP 67.3% 64.0% 65.7% 
FEMALE 
Count 49 54 103 
% within GROUP 32.7% 36.0% 34.3% 
Total 
Count 150 150 300 
% within GROUP 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.370 p=0.543 
In this study among the cases males were 67.3%,females were 
32.7%.Among the control males were 64% and females were 36%. 
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3) DISORDER 
Disorder Frequency Percent 
NEONATAL SEIZURES 26 17.3 
GENERALISED  TONIC CLONIC 
SEIZURES 52 34.7 
COMPLEX PARTIAL SEIZURES 15 10.0 
ATYPICAL FEBRILE SEIZURES 33 22.0 
EPILEPTIC SYNDROMES 15 10.0 
ABSENCE SEIZURES 9 6.0 
Total 150 100.0 
 
In this study the distribution of disorders among cases were neonatal 
seizures (17.3%),generalised tonic clonic seizures(34.7%), complex partial 
seizures(10%), atypical febrile seizures(22%), epileptic syndromes(10%), 
absence seizures(6%). 
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4) DRUG MONOTHERAPY 
Drug Frequency Percent 
SODIUM VALPROATE 69 46.0 
PHENOBARBITONE 49 32.7 
CARBAMAZEPINE 15 10.0 
LEVETIRACETAM 17 11.3 
Total 150 100.0 
 
In this study children on monotherapy were selected 46 % were on 
sodium valproate, 32.7% were on phenobarbitone,10% were on 
carbamazepine,11.3% were on levetiracetam. 
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5) DURATION OF DRUG INTAKE 
Duration Frequency Percent 
3 TO 6MONTHS 14 9.3 
6 TO 12 MONTHS 64 42.7 
1YEAR TO 5 YEAR 68 45.3 
5 YEAR TO 10 YEAR 4 2.7 
Total 150 100.0 
 
Out of 150 children on monotherapy 9.3% were on antiepileptics for 3-6 
months,42.7% for 6-12 months,45.3% for 1-5 years,2.7% for 5-10 years. 
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6) DRUG DOSAGE 
DOSAGE Frequency Percent 
SODIUM VALPROATE 5mg/kg 2 1.3 
SODIUM VALPROATE 10 TO 15 mg/kg 9 6.0 
SODIUM VALPROATE 15 TO 20 mg/kg 37 24.7 
SODIUM VALPROATE 20 TO 25 mg/kg 5 3.3 
SODIUM VALPROATE 25 TO 30 mg/kg 16 10.7 
PHENOBARBITONE 5 mg/kg 49 32.7 
CARBAMAZEPINE 10 to 15 mg/kg 9 6.0 
CARBAMAZEPINE 15 to 20 mg/kg 6 4.0 
LEVETIRACETAM 20 to 25 mg/kg 1 .7 
LEVETIRACETAM 25 to 30 mg/kg 16 10.7 
Total 150 100.0 
 
In this study among the children on sodium valproate 1.3% were on a 
suboptimal dose of 5mg/kg/day,6% were on 10-15mg/kg/day,24.7% were on 
15-20mg/kg/day,3.3s% were on 20-25mg/kg/day,10.7% were on 25-
30mg/kg/day. Among the phenobarbitone group all were on a constant dose of 
5mg/kg/day. Among the carbamazepine group 6% were on 10-15mg/kg/day 
and 4% were on 15-20mg/kg/day 
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Among the levetiracetam group 0.7% were on 20-25mg/kg/day and 
10.7% were on 25-30mg/kg/day. 
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7) SYMPTOMS OF HYPOTHYROIDISM 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid NO 150 100.0 100.0 100.0 
 
In this study none of the children in the cases had symptoms of 
hypothyroidism. 
 
 
 
  
Symptoms of Hypothyroidism
NO
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8) SIGNS OF HYPOTHYROIDISM 
Signs of Hypothyroidism Frequency Percent 
YES 3 2.0 
NO 147 98.0 
Total 150 100.0 
 
In this study only 2% had signs of hypothyroidism. 
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9) TSH VALUES IN CASES AND CONTROL 
Crosstab 
 
GROUP 
Total 
CASE CONTROL 
TSH 
SCORE 
NORMAL 
Count 118 146 264 
% within GROUP 78.7% 97.3% 88.0% 
HIGH 
Count 32 4 36 
% within GROUP 21.3% 2.7% 12.0% 
Total 
Count 150 150 300 
% within GROUP 100.0% 100.0% 100.0% 
Pearson Chi-Square=24.747** p<0.001 
In this study TSH values were normal in 78.7% of cases and increased 
in 21.3% of cases whereas among the control TSH values were normal in 
97.3% of the children and increased in 2.7%.p value is statistically significant. 
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10) Free T3 VALUES IN CASE AND CONTROL 
 
GROUP 
Total 
CASE CONTROL 
ft3group NORMAL Count 144. 149 294 
  % within GROUP 96.67% 99.30% 98.00% 
 LOW Count 6 1 6 
  % within GROUP 4.00% 0.70% 2.00% 
Total  Count 150 150 300 
  % within GROUP 100.00% 100.00% 100.00% 
Pearson Chi-Square=3.657 p=0.056 non significant 
In this study among the cases 96.67% had normal values and 4% had 
low values. Whereas in the control group 99.3% were normal and 0.7% were 
abnormal. p value is non significant. 
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11)  Free T4 VALUES IN CASES AND CONTROL 
 GROUP Total 
CASE CONTROL 
ft4group 
NORMAL 
Count 141 147 288 
% within GROUP 94.0% 98.0% 96.0% 
LOW 
Count 9 3 12 
% within GROUP 6.0% 2.0% 4.0% 
Total 
Count 150 150 300 
% within GROUP 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.125  p=0.077 
In this study among the case 94% had normal freet4 values and 6% had 
low values. Whereas in the control group 98% had normal values and 2% had 
low values.p Value is statistically nonsignificant. 
 
  
91%
92%
93%
94%
95%
96%
97%
98%
99%
100%
CASE CONTROL
94%
98%
6%
2%
T4 NORMAL T4 LOW
 64 
12) TSH values in each group  
Crosstab 
 
TSH_SCORE 
Total 
NORMAL HIGH 
Drug 
SODIUM 
VALPROATE 
Count 44 25 69 
% within 
TSH_SCORE 37.3% 78.1% 46.0% 
PHENOBARBITONE 
Count 43 6 49 
% within 
TSH_SCORE 36.4% 18.8% 32.7% 
CARBAMAZEPINE 
Count 14 1 15 
% within 
TSH_SCORE 11.9% 3.1% 10.0% 
LEVETIRACETAM 
Count 17 0 17 
% within 
TSH_SCORE 14.4% 0.0% 11.3% 
Total 
Count 118 32 150 
% within 
TSH_SCORE 100.0% 100.0% 100.0% 
Pearson Chi-Square=18.071*  p=0.001 significant 
In this study among the children who had high TSH levels 78.1% were 
on sodium valproate,18.8% were on phenobarbitone ,3.1 % were on 
carbamazepine and none were on levetiracetam. P value is statistically 
significant. 
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13) Freet3 values  in each group 
Crosstab 
 
ft3group 
Total 
NORMAL LOW 
Drug 
SODIUM 
VALPROATE 
Count 66 3 69 
% within 
t3group 45.8% 50.0% 46.0% 
PHENOBARBITONE 
Count 47 2 49 
% within 
t3group 32.6% 33.3% 32.7% 
CARBAMAZEPINE 
Count 14 1 15 
% within 
t3group 9.7% 16.7% 10.0% 
LEVETIRACETAM 
Count 17 0 17 
% within 
t3group 11.8% 0.0% 11.3% 
Total 
Count 144 6 150 
% within 
t3group 100.0% 100.0% 100.0% 
Pearson Chi-Square=1.009 p=0.799 non significant 
 
In this study in children with abnormal free t3 values 50% were on 
sodium valproate,33.3% were on phenobarbitone,16.7% were on 
carbamazepine and none on levetiracetam.p value is statistically non 
significant. 
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14) Freet4 values in each group 
 ft4group Total 
NORMAL LOW 
drug 
SODIUM 
VALPROATE 
Count 66 3 69 
% within 
t4group 46.8% 33.3% 46.0% 
PHENOBARBITONE 
Count 45 4 49 
% within 
t4group 31.9% 44.4% 32.7% 
CARBAMAZEPINE 
Count 13 2 15 
% within 
t4group 9.2% 22.2% 10.0% 
LEVETIRACETAM 
Count 17 0 17 
% within 
t4group 12.1% 0.0% 11.3% 
Total 
Count 141 9 150 
% within 
t4group 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.256   p=0.354 non significant 
 
In this study among the children with low freet4 values 33% were on 
sodium valproate,44% were on phenobarbitone,22% were on carbamazepine 
and none were on levetiracetam. P value is statistically non significant. 
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15) Sodium valproate dose and TSH levels 
Crosstab 
 
TSH_SCORE 
Total 
NORMAL HIGH 
DOSAGE 
SODIUM 
VALPROATE 
5mg/kg 
Count 1 1 2 
% within 
TSH_SCORE 2.3% 4.0% 2.9% 
SODIUM 
VALPROATE 10 
TO 15 mg/kg 
Count 6 3 9 
% within 
TSH_SCORE 13.6% 12.0% 13.0% 
SODIUM 
VALPROATE 15 
TO 20 mg/kg 
Count 25 12 37 
% within 
TSH_SCORE 56.8% 48.0% 53.6% 
SODIUM 
VALPROATE 20 
TO 25 mg/kg 
Count 3 2 5 
% within 
TSH_SCORE 6.8% 8.0% 7.2% 
SODIUM 
VALPROATE 25 
TO 30 mg/kg 
Count 9 7 16 
% within 
TSH_SCORE 20.5% 28.0% 23.2% 
Total 
Count 44 25 69 
% within 
TSH_SCORE 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.850 p= 0.932 Non significant  
In this study out of the total 25 children with high TSH levels on sodium 
valproate 4% were on a suboptimal dosage of 5mg/kg/day,12% were on 10-
15mg/kg/day,48% were on 15-20mg/kg/day,8% were on 20-25 mg/kg/day,28% 
were on 25-30 mg/kg/day. p value is statistically non significant. 
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16) Sodium valproate dose and free t3 levels. 
Crosstab 
 
ft3group 
Total 
NORMAL LOW 
DOSAGE 
SODIUM 
VALPROATE 
5mg/kg 
Count 1 1 2 
% within 
t3group 1.5% 33.3% 2.9% 
SODIUM 
VALPROATE 10 
TO 15 mg/kg 
Count 8 1 9 
% within 
t3group 12.1% 33.3% 13.0% 
SODIUM 
VALPROATE 15 
TO 20 mg/kg 
Count 36 1 37 
% within 
t3group 54.5% 33.3% 53.6% 
SODIUM 
VALPROATE 20 
TO 25 mg/kg 
Count 5 0 5 
% within 
t3group 7.6% 0.0% 7.2% 
SODIUM 
VALPROATE 25 
TO 30 mg/kg 
Count 16 0 16 
% within 
t3group 24.2% 0.0% 23.2% 
Total 
Count 66 3 69 
% within 
t3group 100.0% 100.0% 100.0% 
Pearson Chi-Square=12.208  p= 0.016  significant  
In this study out of the 3 children with low freet3 values,one was on 5 
mg/kg/day,one was on 10-15mg/kg/day,one was on 15-20mg/kg/day. 
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17) Sodium valproate and freet4 levels 
DOSAGE * t4group Crosstabulation 
 ft4group Total 
NORMAL LOW 
DOSAGE 
SODIUM 
VALPROATE 
5mg/kg 
Count 2 0 2 
% within 
t4group 3.0% 0.0% 2.9% 
SODIUM 
VALPROATE 10 
TO 15 mg/kg 
Count 9 0 9 
% within 
t4group 13.6% 0.0% 13.0% 
SODIUM 
VALPROATE 15 
TO 20 mg/kg 
Count 35 2 37 
% within 
t4group 53.0% 66.7% 53.6% 
SODIUM 
VALPROATE 20 
TO 25 mg/kg 
Count 5 0 5 
% within 
t4group 7.6% 0.0% 7.2% 
SODIUM 
VALPROATE 25 
TO 30 mg/kg 
Count 15 1 16 
% within 
t4group 22.7% 33.3% 23.2% 
Total 
Count 66 3 69 
% within 
t4group 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.966  p= 0.915 
In this study three children in the sodium valproate group had low freet4 
levels.66.7% were on 15-20mg/kg/day and 33.3% were on 25-30mg/kg/day. 
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18) Phenobarbitone and TSH levels 
 TSH_SCORE Total 
NORMAL HIGH 
DOSAGE PHENOBARBITONE 5 mg/kg 
Count 43 6 49 
% within 
TSH_SCORE 100.0% 100.0% 100.0% 
Total 
Count 43 6 49 
% within 
TSH_SCORE 100.0% 100.0% 100.0% 
No statistics are computed because DOSAGE is a constant. 
In this study 12% of children on phenobarbitone had high TSH levels. 
 
No statistics are computed because DOSAGE is a constant. 
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19) phenobarbitone and freet3 levels 
 ft3group Total 
NORMAL LOW 
DOSAGE PHENOBARBITONE 5 mg/kg 
Count 47 2 49 
% within t3group 100.0% 100.0% 100.0% 
Total 
Count 47 2 49 
% within t3group 100.0% 100.0% 100.0% 
 
In this study 4% of children on phenobarbitone had low freet3 levels. 
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20) Phenobarbitone and freet4 levels 
 ft4group Total 
NORMAL LOW 
DOSAGE PHENOBARBITONE 5 mg/kg 
Count 45 4 49 
% within 
t4group 91.8% 8.2% 100.0% 
Total 
Count 45 4 49 
% within 
t4group 100.0% 100.0% 100.0% 
No statistics are computed because DOSAGE is a constant 
In this study in children on phenobarbitone 8% had low freet4 levels. 
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21) Carbamazepine and TSH levels 
Crosstab 
 
TSH_SCORE 
Total 
NORMAL HIGH 
DOSAGE 
CARBAMAZEP
INE 10 to 15 
mg/kg 
Count 8 1 9 
% within 
TSH_SCORE 57.1% 100.0% 60.0% 
CARBAMAZEP
INE 15 to 20 
mg/kg 
Count 6 0 6 
% within 
TSH_SCORE 42.9% 0.0% 40.0% 
Total 
Count 14 1 15 
% within 
TSH_SCORE 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.714 p=0.396 non significant 
In this study only one child had high TSH values and was on 
carbamazepine 10-15mg/kg/day 
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22) Carbamazepine dose and free t3 levels 
Crosstab 
 ft3group Total 
NORMAL LOW 
DOSAGE 
CARBAMAZEPINE 
10 to 15 mg/kg 
Count 9 0 9 
% within 
t3group 64.3% 0.0% 60.0% 
CARBAMAZEPINE 
15 to 20 mg/kg 
Count 5 1 6 
% within 
t3group 35.7% 100.0% 40.0% 
Total 
Count 14 1 15 
% within 
t3group 100.0% 100.0% 100.0% 
Pearson Chi-Square=1.607  p=0.205 non significant 
In this study only one child on carbamazepine had low t3 values and 
was on 15-20mg/kg/day 
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36%
100%
CARBAMAZEPINE 10 to 15 mg/kg CARBAMAZEPINE 15 to 20 mg/kg
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23) Carbamazepine and freet4 levels 
DOSAGE * t4group Cross tabulation 
 ft4group Total 
NORMAL LOW 
DOSAGE 
CARBAMAZEPINE 
10 to 15 mg/kg 
Count 9 0 9 
% within 
t4group 69.2% 0.0% 60.0% 
CARBAMAZEPINE 
15 to 20 mg/kg 
Count 4 2 6 
% within 
t4group 30.8% 100.0% 40.0% 
Total 
Count 13 2 15 
% within 
t4group 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.462 p= 0.063 
In this study out of the 15 children on carbamazepine only 2 had low t4 
values. 
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24) Levetiracetam and TSH levels 
Crosstab 
 TSH_SCORE Total 
NORMAL 
DOSAGE 
LEVETIRACETAM 
20 to 25 mg/kg 
Count 1 1 
% within 
TSH_SCORE 5.9% 5.9% 
LEVETIRACETAM 
25 to 30 mg/kg 
Count 16 16 
% within 
TSH_SCORE 94.1% 94.1% 
Total 
Count 17 17 
% within 
TSH_SCORE 100.0% 100.0% 
In this study all children on levetiracetam had normal TSH values. 
 
 
  
6%
94%
20-25mg/kg/day 25-30mg/kg/day
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25) Levetiracetam and freet3 values 
Crosstab 
 ft3group Total 
NORMAL 
DOSAGE 
LEVETIRACETAM 
20 to 25 mg/kg 
Count 1 1 
% within t3group 5.9% 5.9% 
LEVETIRACETAM 
25 to 30 mg/kg 
Count 16 16 
% within t3group 94.1% 94.1% 
Total 
Count 17 17 
% within t3group 100.0% 100.0% 
No statistics are computed because t3group is a constant. 
26) Levetiracetam and freet4 levels 
DOSAGE * t4group Crosstabulation 
 ft4group Total 
NORMAL 
DOSAGE 
LEVETIRACETAM 
20 to 25 mg/kg 
Count 1 1 
% within t4group 5.9% 5.9% 
LEVETIRACETAM 
25 to 30 mg/kg 
Count 16 16 
% within t4group 94.1% 94.1% 
Total 
Count 17 17 
% within t4group 100.0% 100.0% 
No statistics are computed because t4group is a constant. 
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DISCUSSION 
The effect of antiepileptic drugs on thyroid function is known for along 
time. There seems to be considerable individual variability of response to 
antiepileptic therapy, probably depending on peripheral changes in the 
hormone metabolism . 
As in children, thyroid hormones are important for normal mental and 
physical growth, the study of the effect of antiepileptic drugs on thyroid 
function is important. 
In this study a total of 150 cases and age and sex matched controls were 
included. In the case group 10% were less than one year,35.3% were from 1-3 
years,34% were from 3-6 years,15.3% 6-10 years,5.3% from 10-12 years. in 
the control group 9.3% were less than one year,32.7% were from 1-3 
years,31.3% were from 3-6 years,16% from 6-10 years,10.7% from 10-12 
years. Among the cases 67.3% were males,32.7% were females. Among the 
control group 64% were males and 36% were females. 
Out of the various seizure disorders generalised tonic clonic type 
accounted to 37%,the next most common seizure type was atypical febrile 
seizure around 22%,17% had neonatal seizures,10% had epileptic syndromes 
and 6% had absence seizures. In this study among the cases 46% were on 
sodium valproate, the next group 32.7% were on phenobarbitone,11.3% were 
on levetiracetam and 10% on carbamazepine. A minimum of 3 months of 
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monotherapy was taken into consideration 9.3% were on medications for 3-6 
months,42.7%for 6-12 months,1-5 years had 45.3% and 5-10 years had 2.7%. 
In this study none of the cases had any symptoms of hypothyroidism and only 
2% had signs of hypothyroidism in the form of mild enlargement of the thyroid 
gland. 
In this study TSH values were normal in 78.7% of the cases and 
elevated in 21.3% of the cases.p value 0.001 was statistically significant. In 
those cases with an elevated TSH levels 78.1% were on sodium valproate 
monotherapy,18.8% were on phenobarbitone and 3.1% were on carbamazepine 
.All children onlevetiracetam had a normal TSH level. Eiris-Punal and 
Vainionpaa et al also had found increased serum TSHlevels(P<0.01) in 
children on sodium valproate and carbamazepine. In those with elevated TSH 
26% were on sodium valproate therapy. 
Several other studies have also shown that anticonvulsants especially 
sodium valproate and phenobarbitone cause an elevation in TSH values causing 
subclinical hypothyroidism. Isojarvi et all conducted a similar study and had 
found increased TSH levels in children on sodium valproate and 
carbamazepine .Attilakos et all had conducted a similar study in children only 
on sodium valproate, in addition to elevated TSH levels low freet3 and freet4 
levels were also noticed. This is in contrast to a study conducted by Alberto et 
all in the university of bologna in which no significant changes in TSH levels 
were noticed in children on sodium valproate. Durdaneet all conducted a study 
on thyroid hormone levels in children on sodium valproate and levetiracetam 
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and found that TSH values were elevated in children on sodium valproate and 
remained unchanged in children on levetiracetam, which is similar to the 
results obtained in this study. 
In this study freet3 values were abnormal in 4% of the cases and in 0.7% 
of the control group.p value was 0.056 that was statistically nonsignificant. 
Among those with low freet3 levels 50% were on sodium valproate,33.3% 
were on phenobarbitone and 16.7% were on carbamazepine. All children on 
levetiracetam had normal freet3 levels. These results are comparable to other 
studies such as Alberto et all who had measured serum freet3 in children on 
long term carbamazepine and sodium valproate and found that there was no 
significant effect on the freet3 levels by the above anticonvulsants.Durdaneet 
all also studied the effect of sodium valproate and levetiracetam on freet3 
levels. Low levels noted in the valproate group turned out to be statistically 
insignificant whereas none of the children on levetiracetam had a low freet3 
values as also noted in this study. All previously mentioned authors found that 
administration of CBZ and VAP did not alter serum free T3level, except for 
Kimura who found that serum freeT3levels were reduced after CBZ 
discontinuation. They suggested that during treatment serum freeT3 level was 
increased and this could be due to an increased conversion of T4 to T3. 
In this study freet4 levels were normal in 94% of the cases, it was 
decreased in 6% of the cases, whereas in the control group freet3 levels were 
normal in 98% of the cases and low in 2% of cases. Among the total of 9 
children with low freet4 levels,4 were on phenobarbitone,3 were on sodium 
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valproate and 2 were on carbamazepine. Levetiracetam group showed no 
reduction in thyroxine levels. Alberto et all ,in his study had found significantly 
reduced freet4 levels in the carbamazepine group and unaffected in the other 
groups whereas in this study no significant difference was noticed even in the 
carbamazepine group of patients.Korkmazet all in his study had also noticed 
low freet3 levels in sodium valproate and phenobarbitone group and no 
significant changes in levetiracetam group of children. 
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CONCLUSION 
1) In this study among the children on anticonvulsant monotherapy sodium 
valproate was themost commonly used drug. 
2) Thyroid profile was altered in children on anticonvulsants. 
3) Significant changes were noticed in TSH levels,abnormal in 
21.3%,majority of them were on sodium valproate(78.1%). 
4) The changes in freet3 and freet4 levels were statistically non significant. 
5) None of the children had any symptoms of hypothyroidism,only 2% had 
signs of hypothyroidism which included goitre on examination. 
 
In this study subclinical hypothyroidism with elevated TSH levels with 
almost all of them showing no signs and symptoms of hypothyroidism was 
noted in children on anticonvulsants except in children on levetiracetam which 
had no effect on thyroid levels. Subclinical hypothyroidism has been found to 
affect cognition of the growing brains in children. Thus periodic monitoring of 
TSH values may be needed in children on anticonvulsants.
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PROFORMA 
1) Name: 
2) Age: 
3) Sex: 
4) OP/IP number: 
5) Residence/ph number: 
6) Type of epilepsy: 
7) Drug Monotherapy: 
8) Duration of treatment: 
9) Dosage of drug: 
10) Compliance: 
11) Symptoms of hypothyroidism 
a. Cold intolerance 
b. Lethargy 
c. Tiredness 
d. Chang of voice 
e. Bowel habits : 
  
f. Growth : 
g. Others 
12) Family history of thyroid abnormality 
13) Drug history: 
14) Menestural history (in females): 
14.1) Normal cycles. 
14.2) Metrorrhagia 
15) 15)Examination: 
15.1) General: 
15.1.1:Pallor: 
1) yes  2)No 
15.1.2:Lethargy: 
1)Yes  2)No 
15.1.3:Pulse: 
1)Normal 2)Bradycardia 
15.1.4: Skin: 
1)Normal 2)Dry 
15.1.5:Goitre: 
1)yes  2)No 
  
15.1.6 other signs of hypothyroidism: 
16) Other systems 
1)normal 2)Abnormal(specify) 
17) Investigations: 
17.1:Serum freeT4 level . 
17.2:Serum free T3 level. 
17.3:Serum TSH level. 
  
  
INFORMED CONSENT FORM 
Study place: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR 
CHILDREN, CHENNAI-08. 
Title of the study: Thyroid profile in children on anticonvulsant monotherapy 
Name of the investigator: Dr. NAMITHA RAJENDRAN 
Name of the Participant:    Age:   Sex: 
Hospital number:    
1. I have read and understood this consent form and the information provided 
to me regarding the participation in the study.  
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the 
investigator.  
5. I have informed the investigator of all the treatments I am taking or have 
taken in the past including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.  
8. I have not participated in any research study in the past. 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital.  
  
10. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent.  
11. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented.  
12. I have understood that my identity will be kept confidential if my data are 
publicly presented  
13. I have had my questions answered to my satisfaction.  
14. I have decided to be in the research study.  
I am aware that if I have any question during this study, I should contact 
the investigator. By signing this consent form I attest that the information given 
in this document has been clearly explained to me and understood by me, I will 
be given a copy of this consent document.  
Name and signature / thumb impression of the participant /parents/guardian  
Name _________________________ Signature_________________  
Date________________  
 
Name and Signature of impartial witness:  
Name _________________________ Signature_________________  
Date________________ 
 
Name and Signature of the investigator or his representative obtaining consent:  
Name _________________________ Signature_________________  
  
  
PATIENT INFORMATION SHEET 
Date________________ 
 
Place of study : Institute Of Child Health And Hospital  
for Children, Egmore, Chennai-8. 
Name of Investigator : Dr.Namitha Rajendran 
Name of Participant:    Age:  Sex:  
Hospital No:      
Study title:  THYROID PROFILE IN CHILDREN ON    
  ANTICONVULSANT MONOTHERAPY 
We request your child to participate in the study. 
Aim of the study: To study the effect of various anticonvulsants on thyroid 
status in children. 
Methods : 
 Clinical examination will be performed on all the admitted 
children to select the study population according to inclusion 
criteria. Prestructured proforma will be used to record the 
relevant information (personal data, clinical findings, laboratory 
findings etc.) of the study population. 
 All children who are selected will be screened for TSH, ft3, ft4, 
levels. 
 
Can I refuse to participate in the study? 
 Participation in the study is purely voluntary. You may refuse to 
participate or withdraw from the study at any time. In both cases the treatment 
and care your child receives from this hospital will not be affected in any 
manner. 
  
  
Benefits and harms of participating in the study: 
Your child will not benefit directly by participating in this study. But by way of 
participating in this study, your child is contributing to updation of science 
which may benefit her/him and all other patients in future. 
Confidentiality: 
 The data collected from the study will be used for the purpose of study 
only. The results of the study will be published. Personal information of the 
children participating in the study will be kept confidential. There will not be 
any disclosure about your child’s information without your permission. 
Subject rights: 
 If you wish further information regarding your child’s rights as a 
research participant, you may contact the principal investigator in the mobile 
number or address mentioned below. 
Principal Investigator – Dr.NAMITHA RAJENDRAN 
Mobile number – 9962952795 
Contact Address  – MD Final year Post Graduate, Institute of Child, 
Health and Hospital for Children, Halls road,  
Egmore, Chennai. 
 
 
 
Place : 
Date:                                                                                  Signature of the Parent 
  
 
  
  
 
  
  
PLAGIARISM CERTIFICATE  
This is to certify that this dissertation work titled THYROID 
PROFILE IN CHILDREN ON ANTICONVULSANT MONOTHERAPY 
of the candidate DR.NAMITHA RAJENDRAN with registration Number 
201517015 for the award of   MD DEGREE in the branch of 
PAEDIATRICS. I personally verified the urkund.com website for the purpose 
of plagiarism Check. I found that the uploaded thesis file contains from 
introduction to conclusion pages and result shows 1 percentage of plagiarism in 
the dissertation. 
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Codings 
AGE 
<1YEAR-1 
1-3 YEARS-2 
3-6 YEARS-3 
6-10YEARS-4 
10-12 YEARS-5 
 
 
SEX 
1-MALE 
2-FEMALE 
 
 
DISORDER 
1-NEONATAL SEIZURES 
2-GENERALISED  TONIC CLONIC SEIZURES 
3-COMPLEX PARTIAL SEIZURES 
4-ATYPICAL FEBRILE SEIZURES 
5-EPILEPTIC SYNDROMES 
6-ABSENCE SEIZURES 
 
 
  
DRUG 
1-SODIUM VALPROATE 
2-PHENOBARBITONE 
3-CARBAMAZEPINE 
4-LEVETIRACETAM 
 
DURATION 
1-3 TO 6MONTHS 
2-6 TO 12 MONTHS 
3-1YEAR TO 5 YEAR 
4-5 YEAR TO 10 YEAR 
5-MORE THAN 10 YEARS 
 
DOSAGE 
a- 5mg/kg 
b- 5 to 10mg/kg 
c- 10 to 15mg/kg 
d- 15 to 20mg/kg 
e- 20 to 25mg/kg 
f- 25 to 30mg/kg 
  
  
SYMPTOMS OF HYPOTHYROIDISM 
1-YES 
2-NO 
 
SIGNS OF HYPOTHYROIDISM 
1-YES 
2-NO 
 
TSH NORMAL RANGE (micro IU/ml) 
<1YEAR-0.70 – 11.0 
1 year to 6 years-  0.73 -5.8 
6year to 12 years-  0.60 -4.80 
 
FreeT3 NORMAL RANGE(pg/ml) 
<1 YEAR- 1.73-6.04 
1 YEAR TO 6 YEARS -2.41 -5.50 
6 YEARS-12 YEARS-2.53 -5.01 
 
FreeT4 NORMAL RANGE(ng/dl) 
<1 YEAR- 0.86 -2.20 
1 YEAR TO 6 YEARS- 0.96 -1.77 
6 YEARS TO 12 YEARS- 0.97 – 1.63 
